0.3450
-0.0050
(-1.43%)
At close: January 17 at 3:58:10 PM GMT+11
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Richard Allman Ph.D. | CEO & Executive Director | 212.31k | -- | 1960 |
| Dr. Andrew N. Stephens | Chief Scientific Officer & Executive Director | 191.07k | -- | -- |
| Prof. Thomas William Jobling | Lead Medical Advisor & Independent Non-Executive Director | 41.74k | -- | -- |
| Ms. Pauline M. Moffatt AAICD, B.Com., BCom, FGIA | Company Secretary | -- | -- | -- |
Cleo Diagnostics Ltd
- Sector:
- Healthcare
- Industry: Medical Devices
Description
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.
Corporate Governance
Cleo Diagnostics Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available